To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.

View sample alert

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Non-Departmental Publication (Policy paper)
HM Prison and Probation Service

Apr. 08 2024

Source Page: Wymott Prison: Action Plan
Document: inspection report for Wymott Prison (PDF)

Found: Preventative screening programmes, including those for bowel cancer were available , and monthly audit

Open Petition since 23rd April 2024

Fund a stroke screening programme using carotid artery scans - 14 Signatures
(Estimated Final Signatures: 136 - 5 added in the past 24hrs)

We want the Government to fund a stroke screening programme, using carotid ultrasound scans to identify risk factors such as narrowing or blockages in the arteries, that will be available to healthy adults in England.

Download petition CSV

Found: common type of stroke, are often caused after arteries in the neck become narrowed, limiting normal blood

Scottish Parliament Written Question
S6W-26204
Friday 5th April 2024

Asked by: Carson, Finlay (Scottish Conservative and Unionist Party - Galloway and West Dumfries)

Question

To ask the Scottish Government what data it holds on how many patients have been diagnosed with a blood cancer through Rapid Cancer Diagnostic Services.

Answered by Gray, Neil - Cabinet Secretary for NHS Recovery, Health and Social Care

The recently published University of Strathclyde evaluation report https://strathprints.strath.ac.uk/88280/7/Maguire-etal-2024-Final-report-of-the-evaluation-of-rapid-cancer-diagnostic-services.pdf showed that 13.5% of cancers diagnosed through the Rapid Cancer Diagnostic Services (RCDS) were blood cancers.

The Scottish Government does not hold data on exact numbers but work is underway with Public Health Scotland to create a national RCDS data-set.

Written Question
Cancer: Medical Treatments
Friday 5th April 2024

Asked by: Lord Wills (Labour - Life peer)

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made, in each of the past five years, of the economic costs of the effects of post-operative cancer treatments.

Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department is working jointly with NHS England and Cancer Alliances to ensure every person receives personalised care and support from cancer diagnosis onwards, including post-treatment. As outlined in the NHS Long Term Plan for cancer, where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan and health and wellbeing information and support. After treatment, the person will move to a follow-up pathway that suits their needs, and ensures they can get rapid access to clinical support, where they are worried that their cancer may have recurred.

Post-operative cancer treatments encompass a wide variety of care, depending on the type and stage of cancer, the treatment the patient has had, and the patient’s needs. Follow-up care often includes regular check-ups, blood tests, scans, and procedures. It may also involve further treatments to deal with late and long-term side effects, including chemotherapy or radiotherapy to reduce the risk of cancer coming back. These highly individualised treatments have varying economic costs.

Non-Departmental Publication (News and Communications)
Medicines and Healthcare products Regulatory Agency

Apr. 04 2024

Source Page: National Patient Safety Alert: ​​Reducing risks for transfusion-associated circulatory overload​ ​(NatPSA/2024/004/MHRA​)
Document: TACO Chapter (PDF)

Found: The implicated component/s were pooled cryoprecipitate and red blood cells in optimal additive solution

Non-Departmental Publication (Guidance and Regulation)
Medicines and Healthcare products Regulatory Agency

Apr. 04 2024

Source Page: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelines
Document: E4 – Dose-Response Information to Support Drug Registration (PDF)

Found: In these cases, a lower starting dose would protect patients who obtain higher blood concentrations.

Non-Departmental Publication (Guidance and Regulation)
Medicines and Healthcare products Regulatory Agency

Apr. 04 2024

Source Page: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelines
Document: M4E(R2) – CTD on Efficacy (PDF)

Found:  relationship between exposure (e.g., drug levels in the blood) and benefit .

Non-Departmental Publication (Guidance and Regulation)
Medicines and Healthcare products Regulatory Agency

Apr. 04 2024

Source Page: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelines
Document: M7(R2) – Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk (PDF)

Found: It is noted that established cancer risk assessments are based on lifetime exposures.

Non-Departmental Publication (Guidance and Regulation)
Medicines and Healthcare products Regulatory Agency

Apr. 04 2024

Source Page: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelines
Document: S1B(R1) – Testing for Carcinogenicity of Pharmaceuticals (PDF)

Found: The surveys were those of the International Agency for Research on Cancer (IARC), the U.S.

Non-Departmental Publication (Guidance and Regulation)
Medicines and Healthcare products Regulatory Agency

Apr. 04 2024

Source Page: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelines
Document: E18 – Genomic Samples and Management of Genomic Data (PDF)

Found: In pediatric subjects, only limited amounts of blood or other tissues may be available and therefore